Adjuvant Endocrine Therapy in Premenopausal Patients.
Endocrine adjuvant therapy is the best-described molecular targeted treatment and should therefore be used for all patients with endocrine-responsive breast cancer. Ta-moxifen for 5 years is standard of care and has proven efficacy in premenopausal patients. The combination of tamoxifen with ovarian function suppression and/or chemotherapy has been extensively tested, and some controversial approaches are used in clinical practice. Cessation or suppression of ovarian function appears to be beneficial for premenopausal patients. Particularly for premenopausal women with highly endocrine-responsive disease and/or low risk for relapse, the additional benefit of cytotoxic chemotherapy may be minor or nonexistent. While the use aromatase inhibitors is investigated in clinical trials, their application outside an academic trial setting cannot be recommended based on first available results. In contrast, the use of adjuvant bispho-sphonates may offer another strategy of further improving clinical outcomes in this important patient subgroup.
Gnant
Michael
M
Universitätsklinik für Chirurgie, Austrian Breast and Colorectal Cancer Study Group, Medizinische Universität Wien, Austria.
J Clin Oncol. 1999 May;17(5):1474-81
10334533
J Clin Oncol. 2001 Jan 15;19(2):343-53
11208825
Lancet. 2005 Aug 6-12;366(9484):455-62
16084253
Cancer. 2008 Mar 1;112(5):1001-10
18205185
J Clin Oncol. 2002 May 15;20(10):2559-66
12011136
Ann Oncol. 2007 Jul;18(7):1133-44
17675394
N Engl J Med. 2004 Mar 11;350(11):1081-92
15014181
Breast Cancer Res Treat. 1997 Apr;43(2):183-90
9131274
Lancet Oncol. 2008 Sep;9(9):840-9
18718815
J Clin Oncol. 2001 Sep 15;19(18):3808-16
11559718
Br J Cancer. 2005 Dec 12;93(12):1319-23
16333242
Lancet. 1998 May 16;351(9114):1451-67
9605801
Breast Cancer Res Treat. 2002 Nov;76(1):27-36
12408373
Lancet. 1996 Apr 20;347(9008):1066-71
8602056
Lancet. 2007 May 19;369(9574):1711-23
17512856
Lancet. 2002 Jun 22;359(9324):2131-9
12090977
Br J Cancer. 2004 Feb 9;90(3):590-4
14760369
Lancet. 2005 May 14-20;365(9472):1687-717
15894097
Cancer Metastasis Rev. 1989 Aug;8(2):98-101
2673568
Lancet. 2000 May 27;355(9218):1869-74
10866443
J Natl Cancer Inst. 2001 May 2;93(9):684-90
11333290
Eur J Cancer. 1998 Apr;34(5):606-8
9713262
N Engl J Med. 2005 Dec 29;353(26):2747-57
16382061
J Clin Oncol. 2007 Mar 1;25(7):829-36
17159193
J Natl Cancer Inst. 2005 Sep 7;97(17):1262-71
16145047
Lancet. 1996 Nov 2;348(9036):1189-96
8898035
J Clin Oncol. 2002 Dec 15;20(24):4611-4
12488402
BMJ. 1997 Oct 4;315(7112):863-6
9353509
Anticancer Res. 1999 May-Jun;19(3B):2261-8
10472341
Lancet Oncol. 2005 Aug;6(8):581-8
16054569
J Natl Cancer Inst. 2007 Dec 19;99(24):1845-53
18073378
Drugs. 2005;65(18):2639-55
16392882
J Clin Oncol. 2002 Dec 15;20(24):4621-7
12488405
J Natl Cancer Inst. 2002 Jul 17;94(14):1054-65
12122096
J Clin Oncol. 2002 Dec 15;20(24):4628-35
12488406
Lancet. 1998 Sep 19;352(9132):930-42
9752815